8-K: Pressure BioSciences Acquires Uncle Buds in All-Stock Deal, Eyes $10M+ Revenue in 2024

Pressure BioSciences has acquired Uncle Buds in an all-stock transaction, aiming to integrate their technologies and achieve over $10 million in revenue in 2024.

Summary

• Pressure BioSciences, Inc. (PBIO) has acquired CBH International LLC, doing business as Uncle Buds, in an all-stock transaction.
• The deal includes the acquisition of all Uncle Buds assets and the assumption of selected liabilities, including a $734,000 long-term loan.
• Uncle Buds stockholders received 127 shares of PBIO convertible Series DD Preferred Stock, which can be converted into 2,540,000 common shares.
• An earnout agreement is in place for up to $4,000,000 in additional PBIO common stock, contingent on achieving revenue and pre-tax income targets in 2024.
• All Uncle Buds employees have become PBIO employees, and Uncle Buds now operates as the Consumer Products Business Unit of PBIO.
• PBIO forecasts over $10 million in revenue for 2024 following the acquisition, a five-fold increase from previous levels.
• The combined entity plans to leverage PBIO's UltraShear technology to enhance Uncle Buds' existing product line and develop new products.

Sentiment

Score: 8

Explanation: The document expresses a highly positive outlook with strong revenue growth projections and strategic benefits from the acquisition. The integration of technology and marketing expertise is presented as a major advantage.

Positives

• The acquisition is expected to be immediately accretive to PBIO's revenue.
• The combined companies are positioned to attract new growth investment and strengthen their balance sheet.
• The acquisition is expected to accelerate PBIO's path to profitability in 2024.
• Uncle Buds brings expertise in branding, celebrity spokesperson management, and online and retail marketing.
• PBIO's UltraShear technology will be incorporated into Uncle Buds' products, creating new market opportunities.
• The combined company has plans for a dozen new product launches in 2024.
• Uncle Buds has an established partnership with Toni Braxton as a marketing ambassador.
• The acquisition is expected to catalyze PBIO's drive to uplist to NASDAQ/NYSE.

Negatives

• The earnout is contingent on achieving specific revenue and pre-tax income targets in 2024, which may not be met.
• The integration of two companies may present challenges and require significant management effort.
• The success of the combined entity depends on the successful integration of PBIO's technology with Uncle Buds' marketing and sales capabilities.

Risks

• The earnout payment is dependent on the achievement of revenue and pre-tax income milestones, which introduces uncertainty.
• The integration of the two companies' operations and cultures may present challenges.
• The combined company's ability to achieve its revenue targets depends on market acceptance of its new products.
• There is a risk that the expected synergies and benefits from the acquisition may not be fully realized.
• The company's ability to uplist to a national stock exchange is not guaranteed and depends on various factors.

Future Outlook

The combined company expects significant revenue growth in 2024 and beyond, driven by the integration of UltraShear technology and the launch of new products. They also aim to attract new growth capital, strengthen their balance sheet, and uplist to a national stock exchange in 2024.

Management Comments

• Richard T. Schumacher, PBIO's President and CEO, stated that the transaction combines Uncle Buds' market execution with PBIO's UltraShear technology for improved product performance.
• Jeffrey N. Peterson, PBIO's Chairman, highlighted the strategic combination of Uncle Buds' marketing skills with PBIO's scientific innovation.
• Bruno Schiavi, President of PBIO Consumer Products, is excited about the potential of the combined company.

Industry Context

This acquisition reflects a trend of companies in the health and wellness sector seeking to combine innovative technologies with established consumer brands to drive growth and market share. The integration of nanoemulsion technology into consumer products is a growing area of interest.

Comparison to Industry Standards

• The acquisition of Uncle Buds by Pressure BioSciences is similar to other deals in the consumer health and wellness space where technology companies acquire brands to leverage their distribution and marketing capabilities.
• The projected revenue growth of 5x to over $10 million in 2024 is ambitious and would place PBIO among the faster-growing companies in the sector if achieved.
• The use of celebrity endorsements, such as Toni Braxton, is a common marketing strategy in the consumer products industry, and Uncle Buds has been successful in this area.
• The focus on nanoemulsion technology is a differentiator for PBIO, as it aims to improve product performance and stability compared to competitors.
• Comparable companies in the CBD and wellness space include Charlotte's Web and CV Sciences, which have also focused on product innovation and brand building.

Management Changes

Stakeholder Impact

• Shareholders are expected to benefit from the increased revenue and growth potential of the combined company.
• Employees of Uncle Buds have transitioned to PBIO, providing them with new opportunities.
• Customers of Uncle Buds will have access to enhanced products through the integration of UltraShear technology.
• Suppliers of both companies may see increased business opportunities due to the combined entity's growth.

Next Steps

• Integrate Uncle Buds' operations and employees into PBIO.
• Incorporate PBIO's UltraShear technology into Uncle Buds' existing product line.
• Develop and launch a dozen new products in 2024.
• Attract new growth investment and strengthen the balance sheet.
• Complete the drive to uplist to a national stock exchange in 2024.

Key Dates

Keywords

acquisition, Pressure BioSciences, Uncle Buds, UltraShear, nanoemulsions, consumer products, CBD, revenue growth, merger, health and wellness